Ajanta Pharma Limited (IN:AJANTPHARM)
:AJANTPHARM
Want to see IN:AJANTPHARM full AI Analyst Report?
Top Page
Ajanta Pharma Limited
(AJANTPHARM)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹3,206.00
▲(9.76% Upside)
Action:ReiteratedDate:08/22/25
Ajanta Pharma Limited's overall stock score is driven by its strong financial performance, which indicates robust growth and stability. The technical analysis suggests a neutral to slightly bearish short-term trend, while the valuation indicates a high P/E ratio, balanced by a moderate dividend yield. The absence of earnings call data and corporate events does not impact the score.
Positive Factors
Revenue Growth
Sustained revenue growth over multiple years indicates successful product launches and expanding market penetration. This durable top-line momentum supports continued reinvestment in higher-value therapies, funds international expansion, and underpins long-term profitability and strategic flexibility.
Negative Factors
Regulatory & Market Access Risk
Expansion into regulated markets depends on successful registrations and partner execution, a structural constraint that can delay revenue realization. Regulatory approvals and partner performance create persistent execution risk that affects long-term geographic diversification and growth pacing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth over multiple years indicates successful product launches and expanding market penetration. This durable top-line momentum supports continued reinvestment in higher-value therapies, funds international expansion, and underpins long-term profitability and strategic flexibility.
Read all positive factors
Ajanta Pharma Limited (AJANTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹345.72B
Dividend Yield1.04%
Average Volume (3M)2.10K
Price to Earnings (P/E)31.6
Beta (1Y)0.40
Revenue Growth14.78%
EPS Growth13.41%
CountryIN
Employees8,073
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)21.91
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.64
Price to Book (P/B)8.64
Price to Sales (P/S)7.14
P/FCF Ratio39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹3,270.00Price Target Upside11.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)101.14
Revenue Forecast (FY)₹60.60B
Ajanta Pharma Limited Business Overview & Revenue Model
Company Description
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-mal...
How the Company Makes Money
Ajanta Pharma primarily makes money by selling pharmaceutical formulations (finished dosage medicines) under its own brands and through its commercial presence in domestic and overseas markets. Its revenue model is centered on (1) domestic branded...
Ajanta Pharma Limited Financial Statement Overview
Summary
Income Statement
87
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.12B | 45.88B | 41.62B | 37.08B | 32.84B | 28.45B |
| Gross Profit | 33.62B | 34.60B | 30.46B | 25.91B | 23.97B | 21.63B |
| EBITDA | 14.31B | 13.54B | 12.57B | 8.81B | 10.44B | 10.24B |
| Net Income | 9.74B | 9.20B | 8.16B | 5.88B | 7.13B | 6.54B |
Balance Sheet | ||||||
| Total Assets | 56.72B | 50.15B | 46.38B | 46.79B | 40.56B | 37.79B |
| Cash, Cash Equivalents and Short-Term Investments | 9.40B | 6.15B | 4.60B | 8.44B | 3.28B | 3.78B |
| Total Debt | 2.46B | 474.20M | 352.80M | 356.30M | 250.30M | 313.60M |
| Total Liabilities | 13.57B | 12.25B | 10.71B | 12.91B | 7.91B | 7.83B |
| Stockholders Equity | 43.15B | 37.90B | 35.67B | 33.88B | 32.64B | 29.96B |
Cash Flow | ||||||
| Free Cash Flow | 1.10B | 8.39B | 6.33B | 6.17B | 4.13B | 4.05B |
| Operating Cash Flow | 2.84B | 11.57B | 7.85B | 7.92B | 5.62B | 5.76B |
| Investing Cash Flow | -5.49B | -3.77B | 653.90M | -5.60B | -741.00M | -2.82B |
| Financing Cash Flow | 1.82B | -7.33B | -10.51B | -1.08B | -4.60B | -3.18B |
Ajanta Pharma Limited Technical Analysis
Negative
2920.85
Price Trends
2901.17
Negative
2788.60
Positive
2666.27
Positive
Market Momentum
-28.55
Negative
44.66
Neutral
61.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJANTPHARM, the sentiment is Negative. The current price of 2920.85 is above the 20-day moving average (MA) of 2841.37, above the 50-day MA of 2901.17, and above the 200-day MA of 2666.27, indicating a neutral trend. The MACD of -28.55 indicates Negative momentum. The RSI at 44.66 is Neutral, neither overbought nor oversold. The STOCH value of 61.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AJANTPHARM.
Ajanta Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹395.24B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹345.72B | 31.59 | ― | 1.04% | 14.78% | 13.41% | |
66 Neutral | ₹321.75B | 36.01 | ― | 0.86% | 9.47% | 17.05% | |
66 Neutral | ₹601.13B | 59.42 | ― | 0.15% | 27.46% | 320.69% | |
61 Neutral | ₹282.43B | 27.13 | ― | 1.07% | 6.70% | 20.25% | |
53 Neutral | ₹648.51B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AJANTPHARM
Ajanta Pharma Limited
2,806.05
71.65
2.62%
IN:GLAND
Gland Pharma Ltd.
1,773.30
373.34
26.67%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,324.85
944.04
68.37%
IN:IPCALAB
IPCA Laboratories Limited
1,537.45
146.48
10.53%
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,047.85
478.04
30.45%
IN:LAURUSLABS
Laurus Labs Ltd.
1,123.85
507.45
82.32%
Ajanta Pharma Limited Corporate Events
Ajanta Pharma Receives US FDA Form 483 With Five Observations at Paithan Plant
Apr 22, 2026
Ajanta Pharma has announced that the U.S. Food and Drug Administration has completed an inspection of its Paithan manufacturing facility in Maharashtra, conducted from April 13 to April 21, 2026. The inspection concluded with the issuance of a For...
Ajanta Pharma Denies Involvement in Rumoured Restaurant Brands Asia Acquisition
Feb 10, 2026
Ajanta Pharma has issued a formal clarification denying media reports that it plans to raise Rs 2,000 crore to acquire Restaurant Brands Asia and diversify into the quick-service restaurant sector. The company stated that the reference to Ajanta P...
Ajanta Pharma Publishes Q3 and Nine-Month FY26 Results in Newspapers in Line with SEBI Norms
Feb 2, 2026
Ajanta Pharma Limited has notified the stock exchanges that it has published its unaudited financial results for the quarter and nine months ended 31 December 2025 in the Mumbai editions of Business Standard and Navakal, in compliance with Regulat...
Ajanta Pharma to Engage Investors at Multiple February 2026 Conferences
Feb 2, 2026
Ajanta Pharma has announced its participation in multiple investor and analyst conferences in February 2026, including Axis Capital’s Flagship India Conference at Trident, BKC, and the Nuvama India Conference 2026 and Kotak Flagship Conferen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.